VACCINE BREAKTHROUGH CASES AMONG HOSPITALISED PATIENTS IN THE INTENSIVE CARE UNIT FOR COVID-19 IN NORTH-EASTERN BULGARIA
DOI:
https://doi.org/10.58395/hb45xe74Keywords:
vaccination, hospitalisation, Bulgaria, intensive care unitAbstract
Background: COVID-19, caused by SARS-CoV-2, continues to spread globally, with vaccines being the most effective way to control the pandemic. Studies show a significant reduction in infection, hospitalisations, severe disease, and death after vaccination.
The aim of the study was to determine the share of breakthrough infections among critically ill patients with severe COVID-19 who had been admitted to the intensive care unit (ICU) of a hospital at the beginning of the delta-variant pick.
Material and methods: For a period of 10 months a total of 740 patients diagnosed with COVID-19, were treated in the intensive care unit of the University Hospital “St. Marina-Varna”, with ersons. Information on the vaccination status of all 740 hospitalised patients was extracted from the National information system "Register of immunized persons against COVID-19", including the type and date of COVID-19 vaccine administration, where available. After that, descriptive statistics were performed with the collected data.
Results: Out of 740 patients, 19 (2.6%) had received at least 1 dose of vaccine, and 721 (97.4%) - none. Only ten (1.35%) of the studied everely and critically ill patients had completed the vaccination cycle (without a booster dose).
Conclusion: Our findings show that when fully administered, vaccines are highly effective against laboratory-confirmed SARS-CoV-2 infection leading to ICU admission. Our findings reinforce the value of widespread COVID-19 vaccination, underscore the importance of completing the vaccination cycle for either of the mRNA-based vaccines, and may help motivate persons who remain hesitant about being vaccinated.
Downloads
References
Francis AI, Ghany S, Gilkes T, Umakanthan S. Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. 2021 Aug 6;0:1–6. https://doi.org/10.1136/postgradmedj-2021-140654
Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF. Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021 Oct 1;21(10):626–36. https://doi.org/10.1038/s41577-021-00592-1
Coronavirus (COVID-19) Vaccinations - Our World in Data [Internet]. [cited 2024 Jan 18];Available from: https://ourworldindata.org/covid-vaccinations
COVID-19 Vaccine Tracker | European Centre for Disease Prevention and Control [Internet]. [cited 2024 Jan 18];Available from: https://vaccinetracker.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#summary-tab
Bulgarian Ministry of Health. Sofia[Internet]. Bulgarian [cited 2022 Feb 16]. Available from: https://www.mh.government.bg/bg/covid-19/dostaveni-v-stranata-vaksini/ Bulgarian
Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study. Lancet Infect Dis;21(7):939–49. https://doi.org/10.1016/S1473-3099(21)00224-3
Bernal JL, Andrews N, Gower C, Robertson C, Stowe J, Tessier E, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ BMJ. 2021 May 13;373:n1088. https://doi.org/10.1136/bmj.n1088
Haas EJ, McLaughlin JM, Khan F, Angulo FJ, Anis E, Lipsitch M, et al. Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study. Lancet Infect Dis. 2021 Sep 22:S1473-3099(21)00566-1. https://doi.org/10.1016/S1473-3099(21)00566-1
Gharpure R, Sami S, Vostok J, Johnson H, Hall N, Foreman A, et al. Multistate Outbreak of SARS-CoV-2 Infections, Including Vaccine Breakthrough Infections, Associated with Large Public Gatherings, United States. Emerg Infect Dis. 2022 Jan;28(1):36–44. https://doi.org/10.3201/eid2801.212220
Bulgarian Ministry of Health. Sofia[Internet]. [cited 2022 Feb 16]. COVID-19 information Bulgarian Available from: https://www.mh.government.bg/bg/covid-19/informaciya-otnosno-noviya-koronavirus-2019-ncov/ Bulgarian
Antonelli M, Penfold RS, Merino J, Sudre CH, Molteni E, Berry S, et al. Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case- control study. Lancet Infect Dis. 2022 Jan;22(1):43–55. https://doi.org/10.1016/S1473-3099(21)00460-6
Cerqueira-Silva T. Influence of age on the effectiveness and duration of protection in vaxzevria and coronavac vaccines. Lancet Reg Health Am. 2022 Feb;6:100154 https://doi.org/10.1016/j.lana.2021.100154
Singer SR, Angulo FJ, Swerdlow DL, McLaughlin JM, Hazan I, Ginish N, et al. Effectiveness of BNT162b2 mRNA COVID-19 vaccine against SARS-CoV-2 variant beta (B.1.351) among persons identified through contact tracing in Israel: A prospective cohort study. Eclinicalmedicine. 2021 Dec;42:101190. https://doi.org/10.1016/j.eclinm.2021.101190
Shrotri M, Krutikov M, Palmer T, Giddings R, Azmi B, Subbarao S, et al. Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study. Lancet Infect Dis. 2021 Nov 1;21(11):1529–38. https://doi.org/10.1016/S1473-3099(21)00289-9
Embi PJ, Levy ME, Naleway AL, Patel P, Gaglani M, Natarajan K, et al. Effectiveness of 2-Dose Vaccination with mRNA COVID-19 Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults — Nine States, January–September 2021. MMWR Morb Mortal Wkly Rep. 2021 Nov 5;70(44):1553–9. https://doi.org/10.15585/mmwr.mm7044e3
Christie A, Henley SJ, Mattocks L, Fernando R, Lansky A, Ahmad FB, et al. Decreases in COVID-19 Cases, Emergency Department Visits, Hospital Admissions, and Deaths Among Older Adults Following the Introduction of COVID-19 Vaccine — United States, September 6, 2020-May 1, 2021. MMWR Recomm Reports. 2021;70(23):858–64. https://doi.org/10.15585/mmwr.mm7023e2
Christie A, Brooks JT, Hicks LA, Sauber-Schatz EK, Yoder JS, Honein MA. Guidance for Implementing COVID-19 Prevention Strategies in the Context of Varying Community Transmission Levels and Vaccination Coverage. MMWR Morb Mortal Wkly Rep. 2021 Jul 27;70(30):1044-1047. https://doi.org/10.15585/mmwr.mm7030e2
Liu Y, Rocklöv J. The reproductive number of the Delta variant of SARS-CoV-2 is far higher compared to the ancestral SARS-CoV-2 virus. J Travel Med. 2021 Oct 11;28(7):taab124. https://doi.org/10.1093/jtm/taab124
Thompson MG, Burgess JL, Naleway AL, Tyner H, Yoon SK, Meece J, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. 2021 Jul 22;385(4):320–9. https://doi.org/10.1056/NEJMoa2107058
Scobie HM, Johnson AG, Suthar AB, Severson R, Alden NB, Balter S, et al. Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status - 13 U.S. Jurisdictions, April 4-July 17, 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1284–90. https://doi.org/10.15585/mmwr.mm7037e1
Tartof SY, Slezak JM, Fischer H, Hong V, Ackerson BK, Ranasinghe ON, et al. Effectiveness of mRNA BNT162b2 COVID-19 vaccine up to 6 months in a large integrated health system in the USA: a retrospective cohort study. Lancet 2021 Oct 16;398(10309):1407-1416. https://doi.org/10.1016/S0140-6736(21)02183-8
Levine-Tiefenbrun M. Viral loads of Delta-variant SARS-CoV2 breakthrough infections following vaccination and booster with the BNT162b2 vaccine. Nat Med 2021 Dec;27(12):2108-2110.; https://doi.org/10.1038/s41591-021-01575-4
Fiolet T, Kherabi Y, MacDonald C-J, Ghosn J, Peiffer-Smadja N. Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. Clin Microbiol Infect. 2022 Feb;28(2):202-221. https://doi.org/10.1016/j.cmi.2021.10.005
Interim Clinical Considerations for Use of COVID-19 Vaccines | CDC [Internet]. [cited 2022 Feb 16]. Available from: https://www.cdc.gov/vaccines/covid-19/clinical-considerations/covid-19-vaccines-us.html
Grannis SJ, Rowley EA, Ong TC, Stenehjem E, Klein NP, DeSilva MB, et al. Interim Estimates of COVID-19 Vaccine Effectiveness Against COVID-19–Associated Emergency Department or Urgent Care Clinic Encounters and Hospitalizations Among Adults During SARS-CoV-2 B.1.617.2 (Delta) Variant Predominance — Nine States, June–August 2021. MMWR Morb Mortal Wkly Rep. 2021 Sep 17;70(37):1291-1293. https://doi.org/10.15585/mmwr.mm7037e2
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Prof. dr Teodora Dimitrova, MD, PhD, Prof. dr Tsonko Paunov, MD, PhD, Ass. Prof. dr. Yavor Chenkov, MD (Author)
This work is licensed under a Creative Commons Attribution 4.0 International License.
